BC Week In Review | Apr 27, 2018
Financial News

Mereo postpones NASDAQ listing

Mereo BioPharma Group plc (LSE:MPH) said on April 26 it postponed an offering to list its ADSs on NASDAQ and withdrew a concurrent placing, citing market conditions. According to an April 9 SEC filing, the...
BC Week In Review | Mar 23, 2018
Clinical News

Mereo's BGS-649 meets in Phase IIb for hypogonadism

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase IIb trial in 271 obese men with hypogonadotropic hypogonadism showing that all three doses of once-weekly oral BGS-649 met the primary endpoint of normalizing...
BC Week In Review | Mar 9, 2017
Clinical News

BGS-649: Ph IIb ongoing

An IDMC recommended continuation of a double-blind, placebo-controlled, international Phase IIb trial evaluating 3 doses of oral BGS-649 once weekly for 24 weeks based on an interim analysis conducted after the first 93 patients completed...
BC Week In Review | Aug 3, 2015
Company News

Novartis, Mereo BioPharma deal

Start-up Mereo acquired three Phase II compounds from Novartis in exchange for an undisclosed equity stake. Novartis is eligible for milestone payments and royalties. BPS-804 is a human mAb for the Orphan bone disease osteogenesis...
BioCentury | Aug 3, 2015

From Phase4 to Mereo

The leadership team behind Phase4 Ventures is branching out from its traditional venture roots to launch newco Mereo BioPharma Group Ltd. , which aims to provide an alternative for pharmas looking to advance mid-stage pipelines in...
BC Extra | Jul 30, 2015
Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

Mereo BioPharma Group Ltd. (London, U.K.) debuted on Wednesday with $119 million (L76.7 million) and three clinical-stage programs acquired from Novartis AG (NYSE:NVS; SIX:NOVN). Woodford Investment Management and Invesco Perpetual invested in Mereo; Novartis also...
Items per page:
1 - 6 of 6